仙琚製藥(002332.SZ):原料藥(苯磺順阿曲庫銨、醋酸環丙孕酮)通過GMP現場檢查
格隆匯5月7日丨仙琚製藥(002332.SZ)公佈,根據浙江省藥品監督管理局近日發佈的“浙江省藥品GMP檢查結果公告(2020年第7號)”,公司原料藥(苯磺順阿曲庫銨、醋酸環丙孕酮)通過GMP現場檢查。
此次通過現場檢查,公司上述品種轉移到原料藥新廠區生產,將有利於公司生產和質量管理體系的提升,為公司原料藥發展奠定堅實基礎。公司將保持穩定的生產管理和質量保證體系,更好地滿足市場需求,保障公司可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.